Drugs / FB849
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05761223 | Dec 2023 → Jun 2026 overdue | neoplasm | 1ST Biotherapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-01 | 1ST Biotherapeutics, Inc. | 퍼스트바이오, AACR 2026서 HPK1 저해제 ‘FB849’ 항암 면역 활성화 기전 공개 1stbio.com ↗ |
| 2026-02-10 | 1ST Biotherapeutics, Inc. | 면역항암제 ‘FB849’ 국내 임상 1/2상 승인 1stbio.com ↗ |
| 2024-03-21 | 1ST Biotherapeutics, Inc. | 퍼스트바이오, AACR에서 ‘HPK1 억제제’ FB849 전임상 연구결과 발표 1stbio.com ↗ |
| 2023-11-14 | 1ST Biotherapeutics, Inc. | 퍼스트바이오, 면역항암제 ‘FB849’ 글로벌 임상 첫 환자 투여 1stbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB849 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761223 ↗ |
| Route | Oral | “Participations will receive FB849 orally once a day.” NCT05761223 ↗ |